PTPI

Petros Pharmaceuticals, Inc.

0.66 USD
+0.05 (+8.52%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Petros Pharmaceuticals, Inc. stock is down -5.43% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 May’s closed higher than April.

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc. is based in New York, New York. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED) It also develops and commercializes H100, a patented topical formulation candidate for the. treatment of acute Peyronie's disease.